Asset Details
Do you wish to reserve the book?
FAPi-PET/CT as surrogate marker for subclinical myocardial fibrosis is a prognostic tool for patients undergoing left-sided heart valve surgery
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
FAPi-PET/CT as surrogate marker for subclinical myocardial fibrosis is a prognostic tool for patients undergoing left-sided heart valve surgery
Do you wish to request the book?
FAPi-PET/CT as surrogate marker for subclinical myocardial fibrosis is a prognostic tool for patients undergoing left-sided heart valve surgery
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
FAPi-PET/CT as surrogate marker for subclinical myocardial fibrosis is a prognostic tool for patients undergoing left-sided heart valve surgery
2026
Overview
Background
The aim of this study was to evaluate fibroblast activation protein (FAP)-targeted positron emission tomography and computed tomography (PET/CT) imaging as surrogate marker for cardiac fibrosis and therefore as prognostic tool for patients with left-sided valvular heart disease undergoing open-heart surgery.
Results
In 13 patients (6 men, 7 women; mean age ± SD, 62 ± 13 years) scheduled for aortic and/or mitral valve surgery (aortic,
n
= 3; mitral,
n
= 9; both,
n
= 1) preoperative FAPi-PET/CT ([
68
Ga]Ga-RTX1363S) was perfomred. FAP-positive volume and FAP uptake was quantified by different methods (isocontour with fixed and variable threshold) and correlated to preoperative clinical parameters, including (left ventricular ejection fraction (LVEF) and serum N-terminal prohormone of brain natriuretic peptide (NT-proBNP), as well as to changes in LVEF from preoperatively to 3–6 months follow-up (available for
n
= 11 patients). FAP-uptake in the left ventricular (LV) myocardium was highly variable in the study cohort. Isocontour-55%-based FAP-positive volume was found to correlate statistically significantly with preoperative LVEF (
p
= 0.03) and preoperative NT-proBNP (
p
= 0.02). In addition, we found a significant correlation with the change in LVEF from preoperatively to 3–6 months follow-up examination (
p
= 0.04).
Conclusions
Preoperative FAPi PET/CT seems to have potential to predict LVEF changes after valvular heart surgery and may therefore be an important tool for risk stratification of asymptomatic patients with left-sided valvular heart disease to support the appropriate timing of valvular surgery.
